Outcome Results of Treatment with Selective Internal Radiation Therapy (SIRT) in Patients with Hepatocellular Carcinoma: A Single Center Experience
- 1 Department of Gastroenterology and Hepatology, University Hospital Heidelberg, Heidelberg, Germany
- 2 Department of Gastroenterology and Hepatology, University Hospital Heidelberg, Heidelberg, Germany
- 3 Department of Gastroenterology and Hepatology, University Hospital Heidelberg, Heidelberg, Germany
- 4 Department of Medical Oncology, National Center for Tumor Diseases Heidelberg, University Hospital Heidelberg, Heidelberg, Germany
- 5 Department of Gastroenterology and Hepatology, University Hospital Heidelberg, Heidelberg, Germany
- 6 Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany
- 7 Department of Gastroenterology and Oncology, Marien-Hospital, Wesel, Germany
- 8 Department of General and Transplant Surgery, University Hospital Heidelberg, Heidelberg, Germany
- 9 Department of General and Transplant Surgery, University Hospital Heidelberg, Heidelberg, Germany
- 10 Department of General and Transplant Surgery, University Hospital Heidelberg, Heidelberg, Germany
- 11 Department of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany
- 12 Department of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany
- 13 Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
- 14 Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
- 15 Department of Gastroenterology and Hepatology, University Hospital Heidelberg, Heidelberg, Germany
- 16 Liver Cancer Center Heidelberg, University Hospital Heidelberg, Heidelberg, Germany
Abstract
Background: Hepatocellular carcinoma (HCC) has a poor prognosis. Selective internal radiation therapy (SIRT) with microspheres is a treatment option for HCC. This study aimed to assess safety and survival (OS) in patients with HCC treated with SIRT, to stratify patients with tumor vascularization and analyze the impact of sequential sorafenib treatment. Methods: Thirty-nine patients who received SIRT for HCC between 2010 and 2013 at our center were included in this retrospective analysis. Tumor vascularization was assessed using a combination of MRI, MAA-scintigraphy and angiography. Tumor vascularization was correlated with survival. Subgroups are treated with two commercially available 90Y-labeled products SIR-Spheres (n = 16) and TheraSpheres (n = 23) and sequential therapy with sorafenib compared to SIRT only was analyzed. Results: Adverse events occurred in 49% of patients with only four grade 3 and no grade 4 event. Median survival for all patients was 12.5 months (95% CI: 8.7 - 16.3). No significant differences were detectable between Thera Spheres or SIR Spheres. Survival was shorter in patients with low tumor vascularization score (OS: 3.8 months (95% CI 0 - 15.0), p = 0.043). Survival was longer with sorafenib upon progression after SIRT (n=16) with an OS of 17.4 months (95% CI: 12.1 – 22.7) compared to no sorafenib (n = 13; 9.1 months; 95% CI: 3.0 - 15.1) or progression upon sorafenib before SIRT (n = 10; 8.6 months; 95% CI: 5.5 - 11.7). Conclusions: SIRT is safe in HCC patients. Tumor vascularization by radiography and scintigraphy may predict survival benefit. Sorafenib is active after SIRT and significantly prolongs survival.
- Llovet, J.M., Bru, C. and Bruix, J. (1999) Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification. Seminars in Liver Disease, 19, 329-338. https://doi.org/10.1055/s-2007-1007122
- Hsu, C.Y., Huang, Y.H., Chiou, Y.Y., Su, C.W., Lin, H.C., Lee, R.C., Chiang, J.H., Huo, T.I., Lee, F.Y. and Lee, S.D. (2011) Comparison of Radiofrequency Ablation and Transarterial Chemoembolization for Hepatocellular Carcinoma within the Milan Criteria: A Propensity Score Analysis. Liver Transplantation, 17, 556-566. https://doi.org/10.1002/lt.22273
- Lee, Y.B., Lee, D.H., Cho, Y., Yu, S.J., Lee, J.H., Yoon, J.H., Lee, H.S., Kim, H.C., Yi, N.J., Lee, K.W., et al. (2015) Comparison of Transarterial Chemoembolization and Hepatic Resection for Large Solitary Hepatocellular Carcinoma: A Propensity Score Analysis. Journal of Vascular and Interventional Radiology, 26, 651-659. https://doi.org/10.1016/j.jvir.2015.02.004
- Burrel, M., Reig, M., Forner, A., Barrufet, M., de Lope, C.R., Tremosini, S., Ayuso, C., Llovet, J.M., Real, M.I. and Bruix, J. (2012) Survival of Patients with Hepatocellular Carcinoma Treated by Transarterial Chemoembolisation (TACE) Using Drug Eluting Beads. Implications for Clinical Practice and Trial Design. Journal of Hepatology, 56, 1330-1335. https://doi.org/10.1016/j.jhep.2012.01.008
- Llovet, J.M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.F., de Oliveira, A.C., Santoro, A., Raoul, J.L., Forner, A., et al. (2008) Sorafenib in Advanced Hepatocellular Carcinoma. The New England Journal of Medicine, 359, 378-390. https://doi.org/10.1056/NEJMoa0708857
- Allison, C. (2007) Yttrium-90 Microspheres (TheraSphere and SIR-Spheres) for the Treatment of Unresectable Hepatocellular Carcinoma. Issues in Emerging Health Technologies, No. 102, 1-6.
- Wong, C.Y., Savin, M., Sherpa, K.M., Qing, F., Campbell, J., Gates, V.L., Lewandowski, R.J., Cheng, V., Thie, J., Fink-Bennett, D., et al. (2006) Regional Yttrium-90 Microsphere Treatment of Surgically Unresectable and Chemotherapy-Refractory Metastatic Liver Carcinoma. Cancer Biotherapy & Radiopharmaceuticals, 21, 305-313. https://doi.org/10.1089/cbr.2006.21.305
- Rhee, T.K., Lewandowski, R.J., Liu, D.M., Mulcahy, M.F., Takahashi, G., Hansen, P.D., Benson3rd, A.B., Kennedy, A.S., Omary, R.A. and Salem, R. (2008) 90Y Radioembolization for Metastatic Neuroendocrine Liver Tumors: Preliminary Results from a Multi-Institutional Experience. Annals of Surgery, 247, 1029-1035. https://doi.org/10.1097/SLA.0b013e3181728a45